Vesatolimod - Gilead Sciences
Alternative Names: GS-9620Latest Information Update: 27 Mar 2025
At a glance
- Originator Gilead Sciences
- Developer Aelix Therapeutics; Gilead Sciences
- Class Amines; Antiretrovirals; Antivirals; Ethers; Pteridines; Pyrrolidines; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 12 Mar 2025 Adverse events data from a phase IIa trial in HIV 1 infections released by Gilead Sciences
- 16 Jan 2025 Gilead Sciences completes phase II FRESH trial in HIV-1 infections in South Africa (IV) (NCT05281510)
- 01 Apr 2024 Phase-I/II clinical trials in HIV-1 infections (Combination therapy, Treatment-experienced) in USA (PO) (NCT06071767)